Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
KAT5
REST API REST API
Homo sapiens
KAT5 is differentially expressed in 234 experiments: 111 organism parts: placenta, cerebellum, ... (109 more);, 150 disease states: normal, lung adenocarcinoma, ... (148 more);, 59 cell types 297 cell lines 38 compound treatments and 74 other conditions.
Synonyms PLIP, TIP60, HTATIP1, ESA1, HTATIP, cPLA2
Orthologs KAT5 (1 of 2) (Danio rerio)   KAT5 (Bos taurus)   Kat5 (Mus musculus)   Kat5 (Rattus norvegicus)   htatip (Danio rerio)   ESA1 (Saccharomyces cerevisiae)   Tip60 (Drosophila melanogaster)   kat5 (Xenopus laevis)   KAT5 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term negative regulation of transcription, DNA-dependent, protein binding, histone acetyltransferase activity, regulation of transcription, DNA-dependent, cytoplasm, NuA4 histone acetyltransferase complex, transferase activity, transferring acyl groups other than amino-acyl groups, metal ion binding, double-strand break repair, transcription coactivator activity, nucleus, histone acetylation, perinuclear region of cytoplasm, transferase activity, chromatin modification, negative regulation of transcription from RNA polymerase II promoter, positive regulation of transcription, DNA-dependent, regulation of growth, nucleolus, androgen receptor binding, androgen receptor signaling pathway, DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator, negative regulation of interleukin-2 production, interspecies interaction between organisms, Piccolo NuA4 histone acetyltransferase complex, repressing transcription factor binding
InterPro Term MOZ_SAS, Chromo_domain/shadow
UniProt Accession Q92993, C9JL99, B4E3C7, E9PMG8, E9PRL6, E9PRM3, E9PJI1
Search EB-eye ENSG00000172977
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-AFMX-5, E-GEOD-6573, E-GEOD-22541, ... (23 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-2450, E-GEOD-4717, ... (32 experiments)

Factor Value U/D Experiments
BT474
3
E-MTAB-37, E-MTAB-62, E-MEXP-440
MCF-7
1
3
E-GEOD-20081, E-GEOD-3529, E-GEOD-5823, E-GEOD-19639
HL-60
2
E-GEOD-24147, E-MTAB-37
LC2/ad
1
E-MTAB-62
NCIH661
1
E-MTAB-37
SNB-75
1
E-MTAB-62
291 more value(s).


Cell type

studied in E-GEOD-20677, E-GEOD-11755, E-GEOD-21750, E-GEOD-2822, E-TABM-34, ... (29 experiments)

Factor Value U/D Experiments
white blood cell
1
E-GEOD-2006
CD34+ hematopoietic progenitor cell
1
1
E-GEOD-19240
endothelial cell
1
E-GEOD-19240
n/a
1
E-MTAB-24
epidermal keratinocyte
1
E-GEOD-2822
CD19+ B cells (neg. sel.)
2
1
E-AFMX-5
53 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-GEOD-15960, E-TABM-15, E-MTAB-62, ... (42 experiments)

Factor Value U/D Experiments
adrenocortical carcinoma
2
E-TABM-311, E-GEOD-10927
colon carcinoma
2
E-MTAB-62, E-MTAB-37
prostate carcinoma
2
E-MTAB-62, E-GEOD-5377
uterine fibroid
2
E-GEOD-7307, E-MTAB-62
lung adenocarcinoma
1
2
E-MTAB-37, E-MTAB-62, E-GEOD-2514
peripheral T-cell lymphoma unspecified
1
E-GEOD-6338
144 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-6907, E-GEOD-5741, E-GEOD-1417, E-GEOD-5824, ... (22 experiments)

Factor Value U/D Experiments
none
1
5
E-GEOD-20719, E-GEOD-5824, E-GEOD-1417, E-MEXP-1958, E-GEOD-2803, ... (6 experiments)
5-aza-2'-deoxycytidine
3
1
E-MEXP-1269
ox-LDL
1
E-GEOD-5741
hydrogen peroxide
1
E-GEOD-5339
dimethyl sulfoxide
1
E-GEOD-5824
N-nitrosodimethylamine
1
E-GEOD-6907
32 more value(s).


Age at diagnosis

studied in E-GEOD-3494, E-GEOD-4922

Factor Value U/D Experiments
75
1
1
E-GEOD-3494
28 years
1
1
E-GEOD-4922


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd4
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-860, E-MEXP-1251, E-GEOD-1563, ... (7 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-5999, E-GEOD-3140, E-GEOD-2666, E-GEOD-4667, E-MTAB-62 ... (5 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-1323, E-GEOD-19743, E-GEOD-22541, E-TABM-147, E-GEOD-21138, ... (6 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-MTAB-73, E-MEXP-1482, E-GEOD-20847, E-MTAB-108, E-MEXP-2340 ... (5 experiments)

Genotype
studied in E-GEOD-1923, E-GEOD-3494, E-MEXP-421, E-GEOD-22593, E-GEOD-2292, ... (8 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-GEOD-5681, E-GEOD-7011, E-MEXP-1446, ... (7 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-MEXP-2069, E-GEOD-1926, E-GEOD-16363, ... (33 experiments)

Infection
studied in E-GEOD-2405, E-MEXP-561, E-GEOD-6802

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-AFMX-1, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-1309, E-GEOD-21750

Population
studied in E-MTAB-197, E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343

Replicate
studied in E-GEOD-10797, E-GEOD-18791

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-101, E-GEOD-3697

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400

Sex
studied in E-GEOD-1643, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-4922, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-16837, E-GEOD-19246, E-GEOD-15799 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-22541, E-GEOD-1561, E-GEOD-4922 ... (5 experiments)

Tumor size
studied in E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.355 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM